Poliomyelitis - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H2 2016, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 2, 5 and 7 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Poliomyelitis Overview 9
Therapeutics Development 10
Pipeline Products for Poliomyelitis - Overview 10
Pipeline Products for Poliomyelitis - Comparative Analysis 11
Poliomyelitis - Therapeutics under Development by Companies 12
Poliomyelitis - Therapeutics under Investigation by Universities/Institutes 14
Poliomyelitis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Poliomyelitis - Products under Development by Companies 18
Poliomyelitis - Products under Investigation by Universities/Institutes 20
Poliomyelitis - Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co Ltd 21
Beijing Tiantan Biological Products Co Ltd 22
Bharat Biotech International Ltd 23
Biken Inc 24
Bilthoven Biologicals BV 25
Biological E Ltd 26
Boryung Pharmaceutical Co Ltd 27
Codagenix Inc 28
Daiichi Sankyo Company Ltd 29
GlaxoSmithKline Plc 30
Grifols SA 31
Johnson & Johnson 32
Kaketsuken KK 33
LG Life Science LTD 34
Nanolek 35
Panacea Biotec Ltd 36
Sanofi Pasteur SA 37
Sentinext Therapeutics Sdn Bhd 38
Shantha Biotechnics Ltd 39
Taiga Biotechnologies Inc 40
Takeda Pharmaceutical Company Ltd 41
Poliomyelitis - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
(diphtheria + haemophilus influenzae [serotype B] + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
BVN-002 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
immune globulin (human) - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ImmunoRx - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
IPVGVI-3000 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
KD-370 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
LBVC - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
LBVD - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
polio (virus like particle, bivalent) vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
polio [strain Sabin] vaccine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
polio vaccine - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
polio vaccine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
polio vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
polio vaccine - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
polio vaccine - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
polio vaccine - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
poliomyelitis vaccine - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
TAK-195 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
VN-0105 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Poliomyelitis - Dormant Projects 80
Poliomyelitis - Discontinued Products 81
Poliomyelitis - Product Development Milestones 82
Featured News & Press Releases 82
Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Number of Products under Development for Poliomyelitis, H2 2016 10
Number of Products under Development for Poliomyelitis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 21
Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2016 22
Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H2 2016 23
Poliomyelitis - Pipeline by Biken Inc, H2 2016 24
Poliomyelitis - Pipeline by Bilthoven Biologicals BV, H2 2016 25
Poliomyelitis - Pipeline by Biological E Ltd, H2 2016 26
Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 27
Poliomyelitis - Pipeline by Codagenix Inc, H2 2016 28
Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 29
Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H2 2016 30
Poliomyelitis - Pipeline by Grifols SA, H2 2016 31
Poliomyelitis - Pipeline by Johnson & Johnson, H2 2016 32
Poliomyelitis - Pipeline by Kaketsuken KK, H2 2016 33
Poliomyelitis - Pipeline by LG Life Science LTD, H2 2016 34
Poliomyelitis - Pipeline by Nanolek, H2 2016 35
Poliomyelitis - Pipeline by Panacea Biotec Ltd, H2 2016 36
Poliomyelitis - Pipeline by Sanofi Pasteur SA, H2 2016 37
Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016 38
Poliomyelitis - Pipeline by Shantha Biotechnics Ltd, H2 2016 39
Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H2 2016 40
Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 41
Assessment by Monotherapy Products, H2 2016 42
Assessment by Combination Products, H2 2016 43
Number of Products by Stage and Target, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Poliomyelitis - Dormant Projects, H2 2016 80
Poliomyelitis - Discontinued Products, H2 2016 81